Rosewind CORP just came out with a new prospectus, available here. This is an SEC requirement for firms looking to issue certain types of securities. An excerpt of the prospectus is provided below:
424B3 1 v444757_424b3.htm 424B3 Prospectus Supplement filed pursuant to Rule 424(b)(3) in connection with Registration Statement No. 333-210144 Aytu BioScience, Inc. Prospectus Supplement No. 2 dated July 22, 2016 (to Prospectus dated May 2, 2016) Warrants to Purchase 763,250 Shares of Common Stock Shares of Common Stock Underlying Warrants to Purchase up to 22,875,000 Shares of Common Stock This Prospectus Supplement No. 2 updates, amends, and supplements the informa tion previously included in the Prospectus Supplement No. 1 dated May 11, 2016 and our prospectus dated May 2, 2016, which we refer to as our prospectus, relating to the offer for sale of warrants to purchase 763,250 shares of common stock, $0.0001 par value per share, and of an aggregate of 22,875,000 shares of common stock, of Aytu BioScience, Inc., upon the exercise of warrants to purchase common stock. Pursuant to the authority granted by Aytu’s stockholders at the annual meeting of stockholders held on May 24, 2016, the Board approved a 1-for-12 reverse stock split of our issued and outstanding shares of common stock, par value $0.0001 per share. We filed with the Secretary of State of the State of Delaware a Certificate of Amendment of our Certificate of Incorporation to implement the reverse stock split effective as of June 30, 2016 at 4:30 p.m. Eastern time. On July 12, 2016, the Board appointed Gary Cantrell as a director and chair of the Compensation Committee, and John Donofrio, Jr., as a director and chair of the Audit Committee, to hold office until the next annual meeting of stockholders. Additionally, Jarrett Disbrow, Chief Operating Officer and a director of the Company, resigned from the Board of Aytu, effective July 7, 2016. Mr. Disbrow will remain as Aytu’s Chief Operating Officer. In connection with Messrs. Cantrell and Donofrio’s appointments to the Board, we granted each of them options to purchase 15,000 shares of our common stock with an exercise price
The above information was disclosed in a filing to the SEC. To see the filing, click here.
To receive a free e-mail notification whenever Rosewind CORP makes a similar move, sign up!
Other recent filings from the company include the following:
Additional definitive proxy soliciting materials and Rule 14(a)(12) material - May 14, 2018
Other preliminary proxy statements - April 27, 2018